Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Rookus

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
British Journal of Cancer|April 15, 2004
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-upR I Olivier, M van Beurden, M A C Lubsen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)M Makama, C A Drukker, E J Th Rutgers, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)" [Eur J Cancer 75 (April 2017) 5-13]M Makama, C A Drukker, E J Th Rutgers, et al.
Contraception|May 1, 1992
Agreement between oral contraceptive users and prescribers: implications for case-control studiesF E van Leeuwen, C M van Duijn, M H Camps, et al.
Gynecologic Oncology|December 13, 2016
Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughtersJ Verloop, F E van Leeuwen, Th J M Helmerhorst, et al.
British Journal of Cancer|July 30, 2005
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriersT C van Sprundel, M K Schmidt, M A Rookus, et al.
British Journal of Cancer|April 12, 2007
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyB B J Hermsen, R I Olivier, R H M Verheijen, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Journal of Medical Genetics|September 6, 2005
Cancer risks in BRCA2 families: estimates for sites other than breast and ovaryC J van Asperen, R M Brohet, E J Meijers-Heijboer, et al.
British Journal of Cancer|April 3, 1999
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2M J Ligtenberg, F B Hogervorst, H W Willems, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
British Journal of Cancer|April 15, 2004
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-upR I Olivier, M van Beurden, M A C Lubsen, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)M Makama, C A Drukker, E J Th Rutgers, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Corrigendum to "An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint<sup>®</sup>)" [Eur J Cancer 75 (April 2017) 5-13]M Makama, C A Drukker, E J Th Rutgers, et al.
Contraception|May 1, 1992
Agreement between oral contraceptive users and prescribers: implications for case-control studiesF E van Leeuwen, C M van Duijn, M H Camps, et al.
Gynecologic Oncology|December 13, 2016
Risk of cervical intra-epithelial neoplasia and invasive cancer of the cervix in DES daughtersJ Verloop, F E van Leeuwen, Th J M Helmerhorst, et al.
British Journal of Cancer|July 30, 2005
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriersT C van Sprundel, M K Schmidt, M A Rookus, et al.
British Journal of Cancer|April 12, 2007
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyB B J Hermsen, R I Olivier, R H M Verheijen, et al.
Familial Cancer|February 22, 2015
Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON studyM R Wevers, M K Schmidt, E G Engelhardt, et al.
Journal of Medical Genetics|September 6, 2005
Cancer risks in BRCA2 families: estimates for sites other than breast and ovaryC J van Asperen, R M Brohet, E J Meijers-Heijboer, et al.
British Journal of Cancer|April 3, 1999
Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2M J Ligtenberg, F B Hogervorst, H W Willems, et al.
Pageof 4